ATE270892T1 - Verwendung einer oligosaccharide enthaltenden dermatologischen zubereitung zur behandlung von hauterkrankungen - Google Patents

Verwendung einer oligosaccharide enthaltenden dermatologischen zubereitung zur behandlung von hauterkrankungen

Info

Publication number
ATE270892T1
ATE270892T1 AT00990076T AT00990076T ATE270892T1 AT E270892 T1 ATE270892 T1 AT E270892T1 AT 00990076 T AT00990076 T AT 00990076T AT 00990076 T AT00990076 T AT 00990076T AT E270892 T1 ATE270892 T1 AT E270892T1
Authority
AT
Austria
Prior art keywords
treatment
preparation containing
skin diseases
containing oligosaccharides
dermatological preparation
Prior art date
Application number
AT00990076T
Other languages
English (en)
Inventor
Gerard Martinez
Christian Francisco
Original Assignee
G Pharm Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G Pharm Lab filed Critical G Pharm Lab
Application granted granted Critical
Publication of ATE270892T1 publication Critical patent/ATE270892T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Botany (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00990076T 1999-12-20 2000-12-20 Verwendung einer oligosaccharide enthaltenden dermatologischen zubereitung zur behandlung von hauterkrankungen ATE270892T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9916060A FR2802414B1 (fr) 1999-12-20 1999-12-20 Composition, notamment cosmetique ou dermatologique, contenant des oligosaccharides, son procede de preparation et un procede de traitement cosmetique
PCT/FR2000/003607 WO2001045713A1 (fr) 1999-12-20 2000-12-20 Composition, notamment cosmetique ou dermatologique, contenant des oligosaccharides, son procede de preparation et un procede de ttraitement cosmetique

Publications (1)

Publication Number Publication Date
ATE270892T1 true ATE270892T1 (de) 2004-07-15

Family

ID=9553473

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04075969T ATE362386T1 (de) 1999-12-20 2000-12-20 Antiallergische zusammensetzung, die oligosaccharide und eine saponine oder eine basische aminosäure enthält, zur topischen verabreichung oder inhalation
AT00990076T ATE270892T1 (de) 1999-12-20 2000-12-20 Verwendung einer oligosaccharide enthaltenden dermatologischen zubereitung zur behandlung von hauterkrankungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04075969T ATE362386T1 (de) 1999-12-20 2000-12-20 Antiallergische zusammensetzung, die oligosaccharide und eine saponine oder eine basische aminosäure enthält, zur topischen verabreichung oder inhalation

Country Status (13)

Country Link
US (1) US6946121B2 (de)
EP (2) EP1464330B1 (de)
JP (1) JP2003518066A (de)
AT (2) ATE362386T1 (de)
AU (1) AU778953B2 (de)
CA (1) CA2395121C (de)
DE (2) DE60034898T2 (de)
DK (1) DK1248630T3 (de)
ES (1) ES2222939T3 (de)
FR (1) FR2802414B1 (de)
PT (1) PT1248630E (de)
TR (1) TR200401935T4 (de)
WO (1) WO2001045713A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629384B2 (en) 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
US7914814B2 (en) 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
JP4178829B2 (ja) 2002-05-02 2008-11-12 株式会社J−オイルミルズ 抗アレルギー性組成物
JP4556009B2 (ja) * 2002-05-31 2010-10-06 塩水港精糖株式会社 抗炎症剤、アレルギー性疾患予防又は改善剤及び機能性食品
EP1529532A1 (de) * 2003-11-07 2005-05-11 Kabushiki Kaisha Honen Corporation Stachyose enthaltende antiallergische Zusammensetzung
CA2556967A1 (en) * 2004-02-23 2005-09-09 Strategic Science & Technologies, Llc Topical delivery of a nitric oxide donor to improve body and skin appearance
FR2868703B1 (fr) * 2004-04-08 2008-06-13 Expanscience Sa Lab Extrait total de lupin constitue d'un extrait de sucres de lupin et d'un extrait peptidique de lupin, procede d'obtention et utilisation
US9050365B2 (en) * 2004-04-19 2015-06-09 Strategic Science & Technologies, Llc Transdermal delivery of beneficial substances effected by a hostile biophysical environment
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
EP2417978A1 (de) * 2004-04-19 2012-02-15 Strategic Science & Technologies, LLC Vorteilhafte Wirkungen der Verstärkung des lokalen Blutflusses
US20090215717A1 (en) * 2004-08-05 2009-08-27 Ivax Drug Research Institute Ltd. Sulfated oligosaccharides
US8153611B2 (en) * 2007-06-28 2012-04-10 Basf Beauty Care Solutions France S.A.S. Use of sulfated oligosaccharides as slimming cosmetic ingredients
FR2917971B1 (fr) 2007-06-28 2009-10-23 Engelhard Lyon Soc Par Actions Composition amincissante
EP2445493A1 (de) 2009-06-24 2012-05-02 Strategic Science & Technologies, LLC Topische zusammensetzung mit naproxen
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
MX337166B (es) 2009-06-24 2016-02-15 Composicion topica que contiene ibuoprofeno.
GB0915315D0 (en) * 2009-09-03 2009-10-07 Univ Manchester Use of non-digestible oligosaccharides
CN103442723A (zh) 2010-12-29 2013-12-11 战略科学与技术有限责任公司 治疗变态反应和其它适应症的系统和方法
ES2811515T3 (es) 2010-12-29 2021-03-12 Strategic Science & Tech Llc Tratamiento de disfunción eréctil y otras indicaciones
US20180015090A1 (en) * 2015-01-28 2018-01-18 Realinn Life Science Limited COMPOUNDS FOR ENHANCING PPARy EXPRESSION AND NUCLEAR TRANSLOCATION AND THERAPEUTIC USE THEREOF

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5777620A (en) * 1980-11-04 1982-05-15 Atsushi Watanabe Carcinostatic agent
JPS59176203A (ja) * 1983-03-28 1984-10-05 Kanebo Ltd 皮膚化粧料
JPS62412A (ja) * 1985-06-25 1987-01-06 Shiseido Co Ltd 化粧料
JPS62277323A (ja) * 1986-02-19 1987-12-02 Sankyo Co Ltd フマル酸ケトチフエン含有点眼液の製法
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
JPH02286078A (ja) * 1989-04-26 1990-11-26 Ajinomoto Co Inc ビフィズス菌増殖促進組成物及びその製造法
JP3665852B2 (ja) * 1998-03-10 2005-06-29 日本甜菜製糖株式会社 抗アトピー性皮膚炎組成物
JP4099267B2 (ja) * 1998-08-07 2008-06-11 株式会社紀文フードケミファ 乳化剤および乳化組成物

Also Published As

Publication number Publication date
FR2802414A1 (fr) 2001-06-22
DE60034898T2 (de) 2008-02-07
CA2395121A1 (fr) 2001-06-28
CA2395121C (fr) 2010-03-16
DK1248630T3 (da) 2004-11-15
FR2802414B1 (fr) 2003-06-27
EP1248630B1 (de) 2004-07-14
DE60034898D1 (de) 2007-06-28
US20030045505A1 (en) 2003-03-06
DE60012230D1 (de) 2004-08-19
PT1248630E (pt) 2004-12-31
EP1248630B9 (de) 2005-01-05
DE60012230T2 (de) 2005-08-04
TR200401935T4 (tr) 2004-10-21
AU2688001A (en) 2001-07-03
EP1464330A1 (de) 2004-10-06
EP1248630A1 (de) 2002-10-16
EP1464330B1 (de) 2007-05-16
ATE362386T1 (de) 2007-06-15
JP2003518066A (ja) 2003-06-03
WO2001045713A1 (fr) 2001-06-28
ES2222939T3 (es) 2005-02-16
US6946121B2 (en) 2005-09-20
AU778953B2 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
DE60012230D1 (de) Verwendung einer oligosaccharide enthaltenden dermatologischen zubereitung zur behandlung von hauterkrankungen
DE3686645T2 (de) Pharmazeutische zusammensetzungen zur verbesserung von wundheilung.
Ramamurthy et al. Diabetes increases collagenase activity in extracts of rat gingiva and skin
Kencka et al. Atrophoderma Pasini-Pierini is a primary atrophic abortive morphea
BR0011640A (pt) ácidos aldÈnicos de oligossacarìdeo e seu uso tópico
JP2993915B2 (ja) ポリホロシドからなる皮膚の上皮剥離を促進するための活性剤、および、ポリホロシドを含有する組成物、並びにその用途
ATE80790T1 (de) Zusammensetzung zur behandlung der haut.
BRPI9909908B8 (pt) conjugados de ácido graxo de sal ou ácido biliar, composição farmacêutica compreendendo os mesmos e seus usos
EP1493431A3 (de) Verwendung eines Extrakts aus Bauhinia zur Herstellung kosmetischer und pharmazeutischer Zubereitungen
DE69426932T2 (de) Verwendung von oligosacchariden zur verhütung und behandlung von alterung der haut
ATE374781T1 (de) Derivate von genkwanin und sakuranetin, deren kosmetische und therapeutische verwendung, und verfahren zu deren herstellung
DE3244321C2 (de) Zusammensetzung für die weibliche Intimhygiene
ATE510544T1 (de) Kosmetische zusammensetzung enthaltend mindestens ein rhamnosemonomer zur kosmetische behandlung der haut
Rasmussen et al. Topical human growth hormone treatment of chronic leg ulcers
Selye Interactions between systemic and local stress
Lorenz‐Meyer et al. Cytotoxicity of lectins on rat intestinal mucosa enhanced by neuraminidase
EP0324745B1 (de) Prostacyclinderivate enthaltende mittel für die topische anwendung
Bernheim et al. Carcinogens and oxidized fatty acids in the skin
KR880005920A (ko) 인체의 백혈구 인터페론 조성물과 피부 치료법
Hajdu et al. Absence of Bowditch phenomenon in the ventricular muscle of hamsters with hereditary cardiomyopathy
Birnbaum Retinoic acid-induced psoriasiform lesions in guinea pigs: antagonism by anti-psoriasis agents
Franke et al. Effects of sublethal doses of a polysaccharide from Serratia marcescens (Bacillus prodigiosus) on the electrocardiogram, blood ascorbic acid, and nonprotein nitrogen of the dog
Iacoviello et al. Different response of vascular fibrinolysis to adrenergic stimulation in young and aged rats
AU2003259006A1 (en) Composition and method for use in intestinal cleansing procedures
BR9805072A (pt) Composição farmacêutica imunoestimulante e seu método de aplicação

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1248630

Country of ref document: EP

REN Ceased due to non-payment of the annual fee